Building a retirement portfolio of $1 million or more is within reach for many Americans. AbbVie (NYSE: ABBV) is a great ...

Shares of AbbVie Inc. (NYSE:ABBV – Get Free Report) have received an average recommendation of “Moderate Buy” from the twenty ...

Discover whether AbbVie or Sanofi holds the edge in the global immunology market and find out which stock shows more ...

By Sabrina Valle NEW YORK (Reuters) -Large deals involving pharmaceutical and biotech companies are stalling as executives ...

We recently published a list of the 15 Best Dividend Aristocrat Stocks with Over 3% Yield. In this article, we are going to ...

AbbVie (ABBV) rebounds after losses, gaining ~% as analysts stay bullish. Discover why its obesity drug deal boosts long-term ...

Imagine standing on a vast, dark plain. Without light, you cannot see dips and rolls in the grass or make out hills and ...

Genmab denies the accusation that it knowingly stole confidential information in a $1.8 billion deal to acquire a cancer drug ...

As AbbVie accuses Genmab of unlawfully using proprietary ADC technology, find out about their collaboration and the dispute ...

AbbVie claims that Genmab turned a blind eye to trade secret theft allegedly used to support the development of ProfoundBio’s ...

Enigma Biomedical USA, Inc. (EB USA) today announced that it is starting a collaboration with the Boston University Chronic Traumatic Encephalopathy (CTE) Center and the Concussion Legacy Foundation.

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.